dorgenmeltucel-L + ipilimumab

**dorgenmeltucel-L + ipilimumab** is a combination immunotherapy regimen being investigated, primarily for advanced melanoma. Dorgenmeltucel-L is an investigational allogeneic cancer vaccine (HyperAcute immunotherapy) derived from genetically modified human melanoma cells designed to present multiple tumor antigens and induce a robust, durable anti-tumor immune response. Ipilimumab is a human monoclonal antibody that functions as a checkpoint inhibitor by blocking cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4), leading to increased T-cell activation and anti-tumor activity. The combination is under evaluation to determine if the immune activation from the vaccine can be amplified by checkpoint blockade, potentially resulting in higher response rates and more durable clinical outcomes for patients with advanced or metastatic melanoma[1][3][4].